Alzheimer's disease: Moving towards a vaccine

Nature

Volumn 454, Issue 7203, 2008, Pages 418-420

  Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; OLIGOMER; TAU PROTEIN;

BRAIN; DISEASE TREATMENT; NERVOUS SYSTEM DISORDER; VACCINE;

ALZHEIMER DISEASE; BIOACCUMULATION; BRAIN REGION; CLINICAL TRIAL; COGNITION; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IMMUNIZATION; MENINGOENCEPHALITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; SHORT SURVEY; TREATMENT RESPONSE;

EID: 47949102462     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/454418a     Document Type: Short Survey

References (11)

1. Hardy, J. & Selkoe, D. J. Science 297, 353-356 (2002).
2. Holmes, C. et al. Lancet 372, 216-223 (2008).
3. Schenk, D. et al. Nature 400, 173-177 (1999).
4. Brody, D. L. & Holtzman, D. M. Annu. Rev. Neurosci. 31, 175-193 (2008).
5. Bayer, A. J. et al. Neurology 64, 94-101 (2005).
6. Orgogozo, J.-M. et al. Neurology 61, 46-54 (2003).
7. Price, J. L. & Morris, J. C. Ann. Neurol. 45, 358-368 (1999).
8. Gómez-Isla, T. et al. J. Neurosci. 16, 4491-4500 (1996).
9. Lewis, J. et al. Science 293, 1487-1491 (2001).
10. Oddo, S. et al. Neuron 43, 321-332 (2004).
11. Fagan, A. M. et al. Ann. Neurol. 59, 512-519 (2006).